Peripheral Arterial Disease
Conditions
Keywords
Ramipril, Angiotensin-converting enzyme, Claudication, Myopathy, Peripheral Arterial Disease
Brief summary
Peripheral artery disease (PAD) is a manifestation of atherosclerosis that produces progressive narrowing and occlusion of the arteries supplying the lower extremities. The most common clinical manifestation of PAD is claudication, i.e., a severe functional limitation identified as gait dysfunction and walking-induced leg muscle pain relieved by rest. The standard therapies for claudication include the medications cilostazol and pentoxifylline, supervised exercise therapy and operative revascularization. Recent data demonstrated that 24 weeks of treatment with the angiotensin-converting enzyme (ACE) inhibitor Ramipril produces improvements in the walking performance of patients with claudication that are higher than those of cilostazol and pentoxifylline and similar to those produced by supervised exercise therapy and operative revascularization. The mechanisms by which Ramipril therapy produces this impressive improvement in the functional capacity of claudicating patients remain unknown. The Investigators hypothesize that treatment of claudicating PAD patients with Ramipril will improve walking performance and quality of life by improving the myopathy of the gastrocnemius. Improved myopathy is a consequence of reduced oxidative damage, reduced TGF-β1 production by vascular smooth muscle cells and reduced collagen deposition in the affected gastrocnemius.
Detailed description
This is an interventional study of PAD patients that exhibit claudication. The purpose of this study is to determine the potential mechanisms by which Ramipril vastly improves the walking performance of these patients. The study will be achieved through these specific aims: Specific Aim #1: Test the hypothesis that Ramipril-mediated improvements of walking parameters among patients with PAD correlate with improvements in both the morphometrics and biochemistry of myofibers in the gastrocnemius of the impaired limb. Specific Aim #2: Test the hypothesis that Ramipril-mediated improvements of walking parameters in patients with PAD correlate with reduced fibrotic events in small vessels and microvasculature, in association with reduced generalized collagen deposition and improved tissue oxygenation, in the gastrocnemius of the impaired limb. Specific Aim #3: Using adult human arterial smooth muscle cells (AHASMC), in vitro, the Investigators will test the hypothesis that the ACE inhibitor Ramipril, which acts as an antagonist of Angiotensin II type 1 receptor (ART1) stimulation by reducing tissue Angiotensin II (Ang II), impedes a mechanism in which Ang II stimulation of ART1 and exposure to hypoxia enhance proliferation of AHASMC and their production of TGF-β1 and collagen, via stimulation of phosphoinositide-3-kinase signaling and suppression of phosphatase and tensin homologue, a master regulator of cell growth. If the above hypotheses are correct, Aims #1 and #2 will demonstrate for the first time that therapy with Ramipril improves the walking performance and quality of life of claudicating PAD patients by improving the myopathy in skeletal muscle of the ischemic lower limbs. The work in Aim #3 will determine the pathways by which hypoxia and Angiotensin II cooperate to induce myopathy in the ischemic muscle. Specific agents targeting these pathways could become new treatments for claudication and for the more advanced stages of PAD characterized by leg rest pain and gangrene.
Interventions
DRUGRamipril
Ramipril therapy will start at 2.5mg/day for 1 week. Then 5mg/day for 1 week and will be increased to 10mg/day by the third week. The patients will stay on Ramipril 10mg/day for 22 weeks.
Sponsors
University of Nebraska
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
1. A positive history of chronic claudication, 2. Exercise-limiting claudication established by history and direct observation during a screening walking test administered by the evaluating vascular surgeon, 3. Arterial occlusive disease per ankle Brachial index measurements and/or other imaging modalities, 4. Stable blood pressure regimen, stable lipid regimen, stable diabetes regimen and risk factor control for 6 weeks.
Exclusion criteria
1. Rest pain or tissue loss due to PAD (Fontaine stage III and IV), 2. acute lower extremity ischemic event secondary to thromboembolic disease or acute trauma, 3. Walking capacity significantly limited by conditions other than claudication including leg (joint/musculoskeletal, neurologic) and systemic (heart, lung disease) pathology, 4. Current use of either ACE inhibitors or angiotensin II receptor blockers, 5. Chronic kidney disease with estimated Glomerular Filtration Rate \< 30 ml/min/1.73 m2, 6. History of bilateral severe renal artery stenosis and 7) History of angioedema related to previous ACE-inhibitor treatment or known hypersensitivity to ramipril or other ACE inhibitors.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Absolute Claudication Distance | 6 months | Maximum walking distance in meters per Gardner protocol |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 6-minute Walking Distance | 6 months | Maximum Distance in meters the patient can walk in 6 minutes on a flat, hard surface |
| Average Daily Steps Taken | 6 months | Monitored with an accelerometer at home |
| Quality of life measured by the Walking Impairment Questionnaire | 6 months | There are 14 questions across three categories of walking distance, walking speed and stair climbing. The WIQ is graded on a scale of 0-4; 0 represents no difficulty; 4 represents inability to walk. 0 score represents no difficulty, 1 score is slight difficulty, 2 score is some difficulty, 3 score is much difficulty, 4 score is unable to complete the task in question. |
| Quality of life measured by the Medical Outcomes Study Short Form 36 Healthy Survey | 6 months | \- (The Short Form 36 Health Survey Questionnaire) has 8 scale (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health) that measures quality of life. The SF-36 scoring ranges from 0-100. Higher scores indicate better health; lower scores indicate more disability |
| Leg biomechanics measured as Vertical ground reaction force | 6 months | measured as Vertical ground reaction force |
| Leg hemodynamics measured as Ankle Brachial Index (ABI) | 6 months | Ratio of the blood pressure at the level of the ankle to the blood pressure at the level of the arm |
| Leg hemodynamics | 6 months | measured as Calf blood flow via contrast-enhanced ultrasound |
| Leg hemodynamics measured as Calf blood flow via stress ABI testing | 6 months | measured as Calf blood flow via stress ABI testing |
| Leg hemodynamics measured as Calf muscle hemoglobin oxygen saturation | 6 months | Measured with Near Infrared Spectroscopy |
| Myofiber Mitochondrial Respiration, measured by polarography | 6 months | measured by polarography |
| Muscle Mitochondrial Function, measured by spectrophotometry | 6 months | measured by spectrophotometry |
| Initial Claudication Distance | 6 months | The distance in meters the patient can walk before he experiences claudication pain, per Gardner protocol |
| Myofiber Morphology, Cross-Sectional Area | 6 months | Area in square microns, measured by immunofluorescence microscopy |
| Myofiber Morphology, Roundness | 6 months | Measured as ratio of major axis in microns to minor axis in microns |
| Myofiber Morphology, Solidity | 6 months | Measured as the ratio of myofiber area in square microns to the area of a fitted convex hull in square microns |
| Muscle Fibrosis, Muscle TGF-β1 | 6 months | Measured as the sum of the products of mean pixel intensity (in gray scale units) and area (in square microns) of each TGF-β1 labeled event divided by the total area (in square microns) of the tissue sample analyzed. Measured by immunofluorescence microscopy. |
| Muscle Fibrosis, Total collagen deposited. | 6 months | Measured as the area-weighted mean pixel intensity (in gray scale units) of all the collagen labeled events per tissue sample. Measured by bright-field microscopy. |
| Microvascular Fibrosis, Capillary wall thickness. | 6 months | Measured in microns by immunofluorescence microscopy of vessels labeled for collagen. |
| Capillary density. | 6 months | Number of capillaries per unit area (in square microns) of the tissue sample analyzed. |
| Serum biomarker of fibrosis, serum procollagen type I c-peptide in picograms of peptide per ml | 6 months | serum procollagen type I c-peptide in picograms of peptide |
| Serum biomarker of fibrosis, serum procollagen type III n-terminal peptide in picograms of peptide per ml | 6 months | serum procollagen type III n-terminal peptide in picograms of peptide per ml |
| Plasma biomarker of fibrosis, plasma TGF-β1 in picograms per ml | 6 months | plasma TGF-β1 in picograms per ml |
| Myofiber Oxidative Damage | 6 months | Myofiber content of HNE adducts and protein carbonyls |
Countries
United States
Contacts
Primary ContactHolly DeSpiegelaere
Outcome results
None listed